Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure

Journal of Virology

Volumn 84, Issue 19, 2010, Pages 10402-10405

  Kim, Eun Young ^a   Bhattacharya, Tanmoy ^b,c   Kunstman, Kevin ^a   Swantek, Peter ^a   Koning, Fransje A ^d   Malim, Michael H ^d   Wolinsky, Steven M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c SANTA FE INSTITUTE   (United States)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTIDINE; LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; MESSENGER RNA; PRIMER DNA; VIRUS RNA;

ADAPTATION; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DEAMINATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPOTHESIS; MUTATION; NATURAL SELECTION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRAL GENETICS; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TYPING; ANTIVIRAL RESISTANCE; CELL LINE; DRUG EFFECTS; GENETIC SELECTION; GENETICS; HUMAN; IN VITRO STUDY; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RNA EDITING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; BASE SEQUENCE; CELL LINE; CYTIDINE DEAMINASE; DNA PRIMERS; DRUG RESISTANCE, VIRAL; GENES, VIRAL; GENETIC VARIATION; HIV-1; HUMANS; IN VITRO TECHNIQUES; LAMIVUDINE; MUTATION; RNA EDITING; RNA, MESSENGER; RNA, VIRAL; SELECTION, GENETIC;

EID: 77956828453     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01223-10     Document Type: Article

References (31)

1. Bishop, K. N., R. K. Holmes, A. M. Sheehy, N. O. Davidson, S. J. Cho, and M. H. Malim. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396.
2. Chiu, Y. L., and W. C. Greene. 2008. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26:317-353.
3. Clavel, F., and A. J. Hance. 2004. HIV drug resistance. N. Engl. J. Med. 350:1023-1035.
4. Coates, J. A., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
5. Domingo, E., and J. J. Holland. 1997. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-178.
6. Duffy, S., L. A. Shackelton, and E. C. Holmes. 2008. Rates of evolutionary change in viruses: patterns and determinants. Nat. Rev. Genet. 9:267-276.
7. Frost, S. D. W., M. Nijhuis, R. Schuurman, C. A. B. Boucher, and A. J. Leigh Brown. 2000. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative role of drift and selection. J. Virol. 74:6262-6268.
8. Gallois-Montbrun, S., B. Kramer, C. M. Swanson, H. Byers, S. Lynham, M. Ward, and M. H. Malim. 2007. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81:2165-2178.
9. Hache, G., L. M. Mansky, and R. S. Harris. 2006. Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev. 8:148-157.
10. Harris, R. S., K. N. Bishop, A. M. Sheehy, H. M. Craig, S. K. Petersen- Mahrt, I. N. Watt, M. S. Neuberger, and M. H. Malim. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
11. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, the RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
12. Jern, P., R. A. Russell, V. K. Pathak, and J. M. Coffin. 2009. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 5:e1000367.
13. Keele, B. F., E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J. L. Kirchherr, F. Gao, J. A. Anderson, L. H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A. Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C. Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C. Seoighe, A. S. Perelson, T. Bhattacharya, B. T. Korber, B. H. Hahn, and G. M. Shaw. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
14. Koning, F. A., E. N. Newman, E. Y. Kim, K. J. Kunstman, S. M. Wolinsky, and M. H. Malim. 2009. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83:9474-9485.
15. Malim, M. H., and M. Emerman. 2008. HIV-1 accessory proteins - ensuring viral survival in a hostile environment. Cell Host Microbe 3:388-398.
16. Mangeat, B., P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103. (Pubitemid 36834849)
17. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
18. Marin, M., K. M. Rose, S. L. Kozak, and D. Kabat. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403.
19. Moya, A., E. C. Holmes, and F. Gonzalez-Candelas. 2004. The population genetics and evolutionary epidemiology of RNA viruses. Nat. Rev. Microbiol. 2:279-288.
20. Mulder, L. C., A. Harari, and V. Simon. 2008. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 105:5501-5506.
21. Posada, D., K. A. Crandall, and E. C. Holmes. 2002. Recombination in evolutionary genomics. Annu. Rev. Genet. 36:75-97.
22. Rose, P. P., and B. T. Korber. 2000. Detecting hypermutations in viral sequences with an emphasis on G → A hypermutation. Bioinformatics 16:400-401.
23. Sadler, H. A., M. D. Stenglein, R. S. Harris, and L. M. Mansky. 2010. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 84:7396-7404.
24. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
25. Sheehy, A. M., N. C. Gaddis, and M. H. Malim. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407.
26. Stopak, K., C. de Noronha, W. Yonemoto, and W. C. Greene. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601.
27. Verhulst, P.-F. 1838. Notice sur la loi que la population poursuit dans son accroissement, p. 113-121. In J. G. Garnier and A. Quetelet (ed.), Correspondance mathématique et physique, vol. 10. Société Belge de Librairie, Brussels, Belgium.
28. Wood, N., T. Bhattacharya, B. F. Keele, E. Giorgi, M. Liu, B. Gaschen, M. Daniels, G. Ferrari, B. F. Haynes, A. McMichael, G. M. Shaw, B. H. Hahn, B. Korber, and C. Seoighe. 2009. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog. 5:e1000414.
29. Yu, Q., R. Konig, S. Pillai, K. Chiles, M. Kearney, S. Palmer, D. Richman, J. M. Coffin, and N. R. Landau. 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11:435-442.
30. Yu, X., Y. Yu, B. Liu, K. Luo, W. Kong, P. Mao, and X. F. Yu. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
31. Zhang, H., B. Yang, R. J. Pomerantz, C. Zhang, S. C. Arunachalam, and L. Gao. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.